Table 3. Trends in OMEQe (mg) prescribing stratified by deprivation.
| Oral or transdermal opioids | ||
| Deprivation quintile | Total daily OMEQe dose (mg) prescribed | Total daily OMEQe dose (mg) per 1000 population |
| WIMD1 | ||
| 2005 | 10 319 636 | 21 757 |
| 2015 | 21 167 919 | 43 176 |
| Rate change, % | 105.1 | 98.4 |
| Total prescribeda | 176 824 265 | |
| WIMD2 | ||
| 2005 | 8 590 375 | 18 203 |
| 2015 | 17 399 026 | 35 475 |
| Rate change, % | 102.5 | 94.9 |
| Total prescribeda | 146 459 878 | |
| WIMD3 | ||
| 2005 | 7 684 060 | 17 108 |
| 2015 | 15 342 942 | 32 564 |
| Rate change, % | 99.7 | 90.3 |
| Total prescribeda | 129 880 669 | |
| WIMD4 | ||
| 2005 | 5 374 595 | 12 242 |
| 2015 | 10 878 897 | 23 534 |
| Rate change, % | 102.4 | 92.2 |
| Total prescribeda | 93 691 687 | |
| WIMD5 | ||
| 2005 | 4 486 035 | 9 381 |
| 2015 | 8 721 170 | 17 557 |
| Rate change, % | 94.4 | 87.2 |
| Total prescribeda | 76 112 569 | |
aTotal prescribed 2005–2015. Annual OMEQe calculated as per method and stratified by deprivation quintile (Welsh Index of Multiple Deprivation [WIMD2011], where WIMD1 = most deprived, WIMD5 = least deprived). OMEQe = estimated oral morphine equivalent.